| highly potent incretin receptor agonists semaglutide and tirzepatide | Decreases - reduced risk | premature mortality | Human | patients with type 2 diabetes and obesity | — | GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management. |
| GLP-1RAs semaglutide and tirzepatide | Decreases - had a lower risk | all-cause mortality | Human | adults with type 2 diabetes and obesity | — | Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. |
| GLP-1RAs semaglutide and tirzepatide | Decreases - greater benefits | risk of dementia, stroke, and all-cause mortality | Human | patients aged 60 years or older | — | Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. |
| GLP-1RAs semaglutide and tirzepatide | Decreases - greater benefits | risk of dementia, stroke, and all-cause mortality | Human | women | — | Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. |
| GLP-1RAs semaglutide and tirzepatide | Decreases - greater benefits | risk of dementia, stroke, and all-cause mortality | Human | patients with a body mass index of 30 to 40 | — | Neurodegeneration and Stroke After Semaglutide and Tirzepatide in Patients With Diabetes and Obesity. |
| semaglutide | Decreases - reduced the risk of | all-cause mortality | Human | patients with HFpEF or HFmrEF | — | Comparative Effectiveness of Glucagon-like Peptide-1- Receptor Agonists in Patients With Heart Failure With Preserved or Minimally Reduced Ejection Fraction: A Comprehensive Bayesian Network Meta-Analysis and Network Meta-Regression. |
| semaglutide | No effect - did not affect | cardiovascular mortality | Human | patients with HFpEF or HFmrEF | — | Comparative Effectiveness of Glucagon-like Peptide-1- Receptor Agonists in Patients With Heart Failure With Preserved or Minimally Reduced Ejection Fraction: A Comprehensive Bayesian Network Meta-Analysis and Network Meta-Regression. |
| semaglutide | Decreases - conclusively shown to have cardioprotective effects | cardiovascular mortality | Human | patients with diabetes | Not specified | Evidence-Based Cardiovascular Risk Management in Diabetes.cited 10× |
| semaglutide | No effect - absence of reduction | cardiovascular mortality | Human | — | — | Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists. |
| semaglutide | Decreases - showed more than 40% risk reduction | composite of hospitalization for heart failure or all-cause mortality | Human | patients with cardiometabolic HFpEF | — | Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction. |
| once weekly semaglutide | Decreases - decreased the incidence | major adverse CV events and mortality | Human | — | — | Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns. |
| liraglutide and semaglutide | Decreases - proved to be superior | CV morbidity and mortality | Human | patients with type 2 diabetes | — | Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors. |
| Oral semaglutide | Decreases - shows more significant advantages in reducing | all-cause mortality | Human | patients | — | Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis. |
| Oral semaglutide | Decreases - shows more significant advantages in reducing | cardiovascular mortality | Human | patients | — | Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis. |
| semaglutide 2.4mg sc | Decreases - has shown a reduction | cardiovascular mortality | Human | — | — | GLP-1 receptor agonists in obesity treatment: Effects on cardiometabolic variables and cardiovascular disease. |
| cagrilintide/semaglutide, liraglutide, semaglutide and tirzepatide | No effect - effects | cardiovascular mortality | Human | patients with and without a history of HF | — | Cardiovascular effects of incretin-based drugs in patients with and without a history of heart failure: a protocol for a systematic review, meta-analysis and trial sequential analysis of randomised controlled trials. |
